Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in Accra

Table 4

Risk factors for EPF positive score.

	EPF Positive; (𝑛=59); 𝑛 (%)	EPF Negative; (𝑛=344); 𝑛 (%)	𝑃 value
Male	38 (64.4)	166 (48.3)	0.012*
Average age (months)	97.7 ± 45.6	107.6 ± 40.5	0.088**
Average age at diagnosis (months)	46.3 ± 40.0	59.1 ± 37.0	0.002*
Total exposure time to HAART (months)^†	49.1 ± 24.4	47.3 ± 26.0	0.469
Age at HAART initiation (months)^†	55.5 ± 43.1	71.2 ± 37.0	0.003*
Current WHO stage			<0.0001*
I	4 (6.8)	47 (13.8)
II	5 (8.4)	73 (21.4)
III	21 (35.6)	146 (42.8)
IV	29 (49.2)	75 (22.0)
Number of HAART regimen switches^†	3 (5.67)	18 (6.48)	0.532
Nonadherent^†	10 (18.87)	84 (30.22)	0.093**

∗Statistical significance (𝑃<0.05).
∗∗(𝑃<0.10).
†Calculated using only those patients who are on HAART (𝑛=331, with 53 EPF Positive/278 EPF Negative).